Clinical Trial Update: Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating panobinostat in combination with bortezomib and dexamethasone in Japanese patients with relapsed/refractory multiple myeloma has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapse Refractory Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Panobinostat (Panobinostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapse/Refractory Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2019-11-18